Global Cancer Supportive Care Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Cancer Supportive Care Drugs Market is presumed to reach the valuation of nearly USD 27.32 MN by 2030 from USD 19.21 MN in 2022 with a CAGR of 4.5% during the period of 2023-2030.

Cancer care supportive drugs are those drugs that are used to reduce the injurious side effects of cancer treatment by protecting specific organs or cells. These drugs are not used for cancer treatment. Supportive drugs are sometimes also called as protective drugs. The major drug classes involved in cancer supportive care include ESAs for the treatment of Anemia (CIA), G-CSFs for neutropenia (CIN), bisphosphonates for cancer-induced bone diseases, antiemetics for nausea and vomiting (CINV), and NSAIDs for treating cancer pain. The side effects of cancer supportive drugs will depend primarily on: drug type, the dose given, and the overall health of the patients.

Market Dynamics:

The increasing prevalence of cancer globally and many side effects associated with cancer treatment are the major factors driving the cancer supportive care drug market over the forecast time frame. In addition to that, increasing uptake of biosimilars and the availability of effective treatment methods are other factors that add fuel to the growth of the cancer supportive care drugs market. Also, rising expenditure on healthcare and beneficial healthcare reforms worldwide are positively impacting market growth. Moreover, the technological advancements in targeted therapy drugs, which have lesser side effects than traditional cancer therapy drugs, is anticipated to give rise to more demand in the coming years.

The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.

Additionally, these tools also give inclusive assessment of each application/product segment in the global market of cancer supportive care drugs.

Market Segmentation:

The entire cancer supportive care drugs market has been sub-categorized into therapeutic class. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.

By Therapeutic Class

G-CSFs (Granulocyte-colony Stimulating Factors)
ESAs (Erythropoiesis Stimulating Agents)
Anti-Emetics
Bisphosphonates
Opioids
(Non Steroidal Anti-Inflammatory Drugs) NSAIDs

Regional Analysis:

This section covers regional segmentation which accentuates on current and future demand for cancer supportive care drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cancer supportive care drugs market include Amgen Inc, Merck & Co. Inc., Johnson & Johnson Services Inc., Heron Therapeutics Inc., Novartis AG, GlaxoSmithKline plc (GSK), F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11213519

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Cancer Supportive Care Drugs Market
2.2. Global Cancer Supportive Care Drugs Market Snapshot

3 . CANCER SUPPORTIVE CARE DRUGS - INDUSTRY ANALYSIS

3.1. Introduction
3.2. Market Drivers of Cancer Supportive Care Drugs Market
3.3. Market Restraints of Cancer Supportive Care Drugs Market
3.4. Opportunities of Cancer Supportive Care Drugs Market
3.5. Trends of Cancer Supportive Care Drugs Market
3.6. Porter's Five Force Analysis of Cancer Supportive Care Drugs Market
3.7. Cancer Supportive Care Drugs Market Attractiveness Analysis
- 3.7.1 Market Attractive Analysis by Therapeutic Class
- 3.7.2 Market Attractive Analysis by Region

4 . VALUE CHAIN ANALYSIS

4.1. Cancer Supportive Care Drugs Value Chain Analysis
4.2. Cancer Supportive Care Drugs Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Cancer Supportive Care Drugs Raw Material Manufactures List
- 4.2.3. Price Trend of Cancer Supportive Care Drugs Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS

6.1 Overview by Therapeutic Class
6.2 Historical Data 2015-2018
6.3 Global Cancer Supportive Care Drugs Market Analysis by Therapeutic Class
6.4 Market Analysis of G-CSFs (Granulocyte-colony Stimulating Factors) by Regions
6.6 Market Analysis of ESAs (Erythropoiesis Stimulating Agents) by Regions
6.5 Market Analysis of Anti-Emetics by Regions
6.7 Market Analysis of Bisphosphonates by Regions
6.8 Market Analysis of Opioids by Regions
6.9 Market Analysis of (Non Steroidal Anti-Inflammatory Drugs) NSAIDs by Regions

7 . GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America
- 7.3.1. Overview and Historic Data
- 7.3.2. North America Cancer Supportive Care Drugs Market Estimate By Market Segment
- 7.3.3. North America Cancer Supportive Care Drugs Market Estimate By Country
- 7.3.4. United State
- 7.3.5. Canada
- 7.3.6. Mexico
7.4. Europe
- 7.4.1. Overview and Historic Data
- 7.4.2. Europe Cancer Supportive Care Drugs Market Estimate by Market Segment
- 7.4.3. Europe Cancer Supportive Care Drugs Market Estimate by Country
- 7.4.4. United Kingdom
- 7.4.5. France
- 7.4.6. Germany
- 7.4.7. Italy
- 7.4.8. Russia
- 7.4.9. Rest Of Europe
7.5. Asia Pacific
- 7.5.1. Overview and Historic Data
- 7.5.2. Asia Pacific Cancer Supportive Care Drugs Market Estimate by Market Segment
- 7.5.3. Asia Pacific Cancer Supportive Care Drugs Market Estimate by Country
- 7.5.4. China
- 7.5.5. India
- 7.5.6. Japan
- 7.5.7. South Korea
- 7.5.8. Australia
- 7.5.9. Rest Of Asia Pacific
7.6. Latin America
- 7.6.1. Overview and Historic Data
- 7.6.2. Latin America Cancer Supportive Care Drugs Market Estimate by Market Segment
- 7.6.3. Latin America Cancer Supportive Care Drugs Market Estimate by Country
- 7.6.4. Brazil
- 7.6.5. Argentina
- 7.6.6. Peru
- 7.6.7. Chile
- 7.6.8. Rest of Latin America
7.7. Middle East & Africa
- 7.7.1. Overview and Historic Data
- 7.7.2. Middle East & Africa Cancer Supportive Care Drugs Market Estimate by Market Segment
- 7.7.3. Middle East & Africa Cancer Supportive Care Drugs Market Estimate by Country
- 7.7.4. Saudi Arabia
- 7.7.5. UAE
- 7.7.6. Israel
- 7.7.7. South Africa
- 7.7.8. Rest Of Middle East And Africa

8 . COMPETITIVE LANDSCAPE OF THE CANCER SUPPORTIVE CARE DRUGS COMPANIES

8.1. Cancer Supportive Care Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF CANCER SUPPORTIVE CARE DRUGS INDUSTRY

9.1. Company Share Analysis
9.2. Market Concentration Rate
9.3. Amgen Inc.
- 9.3.1. Company Overview
- 9.3.2. Financials
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Merck & Co.
- 9.4.1. Company Overview
- 9.4.2. Financials
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Johnson & Johnson Services, Inc.
- 9.5.1. Company Overview
- 9.5.2. Financials
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Heron Theovartis
- 9.6.1. Company Overview
- 9.6.2. Financials
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Novartis AG
- 9.7.1. Company Overview
- 9.7.2. Financials
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. GlaxoSmithKline plc (GSK)
- 9.8.1. Company Overview
- 9.8.2. Financials
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. F. Hoffmann-La Roche Ltd.
- 9.9.1. Company Overview
- 9.9.2. Financials
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Helsinn Healthcare SA
- 9.10.1. Company Overview
- 9.10.2. Financials
- 9.10.3. Products
- 9.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies